MET and non-small cell lung carcinoma: For example, cMET is aberrantly active in malignancy and involved in tumor growth and angiogenesis, and a cMET inhibitor (savolitinib) has been approved for the treatment of the 2–4% of non‐small cell lung cancers (NSCLC) that harbor cMET mutations (Li et al, 2022).